Live Breaking News & Updates on Rene Braeckman

Stay updated with breaking news from Rene braeckman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IH Drug Candidate Tolerated Across Doses, Interim Data Shows

Interim data from a phase 2 trial of KP1077 in patients with IH indicates the drug is well-tolerated at all tested doses and dosing schedules. ....

Rene Braeckman , Zevra Therapeutic ,

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Nichol Ochsner , Janine Bogris , Rene Braeckman , Us Drug Enforcement Agency , Clinical Development , Exchange Commission , Zevra Therapeutics Inc , Drug Administration , Senior Vice President , Epworth Sleepiness Scale , Patient Global Impression , Clinical Global Impression , Idiopathic Hypersomnia Severity Scale , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Zevra Therapeutics , Note Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Investor Inquiries , Media Inquiries ,

KP1077 Rivals Ritalin in Heart Safety for Idiopathic Hypersomnia

Zevra Therapeutics highlighted the heart safety of SDX, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia. ....

Rene Braeckman , Psych Congress , Zevra Therapeutics ,

Zevra Therapeutics Presents Full Data Set on the

CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics. ....

United States , Jennifer Arcure , Rene Braeckman , Nichol Ochsner , Psych Congress Poster Award Reception On , Us Drug Enforcement Agency , Corium Inc , Clinical Development At Zevra , Psych Congress , Zevra Therapeutics Inc , Clinical Development , Drug Administration , Exchange Commission , Vice President , Psych Congress Poster Award Reception , Single Dose Crossover Study , Healthy Volunteers , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Zevra Therapeutics , Note Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Priority Review Voucher , Annual Report , Quarterly Report ,

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

CELEBRATION, Fla., Sept. 09, 2023 Zevra Therapeutics, Inc. , a rare disease therapeutics company, today announced a poster presentation featuring study data that underscores the cardiovascular. ....

United States , Nichol Ochsner , Rene Braeckman , Jennifer Arcure , Us Drug Enforcement Agency , Corium Inc , Drug Administration , Zevra Therapeutics Inc , Clinical Development , Exchange Commission , Psych Congress Poster Award Reception , Globenewswire Inc , Psych Congress , Clinical Development At Zevra , Vice President , Single Dose Crossover Study , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Zevra Therapeutics , Note Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Priority Review Voucher , Annual Report , Quarterly Report , Media Inquiries ,